Trial NCT03926143

View at ClinicalTrials.gov 
Org. Study IDs: 20322
Secondary IDs: 2019-000061-20

Last trial update was posted on 2023-08-04

MeSH Interventions

Anetumab ravtansine Maytansine Tubulin Modulators

MeSH Conditions

Neoplasms

Other Conditions

Solid Tumors

Stopping Reasons

Due to strategic company decisions, the development of anetumab ravtansine was stopped.

Limitations And Caveats

Due to the small sample size and heterogeneous population, survival distributions and the extent of long-term survival in the applicable populations cannot be reliably estimated from the study results. Overall results were reported. Pooling was done because there is only a single patient treated with combination and no summary tables on a single patient.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID